Related Experiment Video
Updated: Jun 4, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β
Fahd Al-Mulla1, Milad S Bitar, May Al-Maghrebi
1Department of Pathology, Faculty of Medicine, Health Sciences Center, Kuwait University, Safat, Kuwait, UK. fahd@al-mulla.org
Abstract:
Raf kinase inhibitory protein (RKIP) is a physiologic inhibitor of c-RAF kinase and nuclear factor κB signaling that represses tumor invasion and metastasis. Glycogen synthase kinase-3β (GSK3β) suppresses tumor progression by downregulating multiple oncogenic pathways including Wnt signaling and cyclin D1 activation. Here, we show that RKIP binds GSK3 proteins and maintains GSK3β protein levels and its active form. Depletion of RKIP augments oxidative stress-mediated activation of the p38 mitogen activated protein kinase, which, in turn, inactivates GSK3β by phosphorylating it at the inhibitory T390 residue. This pathway de-represses GSK3β inhibition of oncogenic substrates causing stabilization of cyclin D, which induces cell-cycle progression and β-catenin, SNAIL, and SLUG, which promote epithelial to mesenchymal transition. RKIP levels in human colorectal cancer positively correlate with GSK3β expression. These findings reveal the RKIP/GSK3 axis as both a potential therapeutic target and a prognosis-based predictor of cancer progression.
Insights
Raf kinase inhibitory protein (RKIP) maintains active Glycogen synthase kinase-3β (GSK3β), suppressing cancer progression. RKIP depletion activates a pathway that inactivates GSK3β, promoting tumor invasion and metastasis.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Raf kinase inhibitory protein (RKIP) inhibits c-RAF kinase and NF-κB signaling, repressing tumor invasion and metastasis.
- Glycogen synthase kinase-3β (GSK3β) suppresses tumor progression by downregulating oncogenic pathways like Wnt signaling and cyclin D1 activation.
Purpose of the Study:
- To investigate the interaction between RKIP and GSK3β.
- To elucidate the role of RKIP in regulating GSK3β activity and its downstream effects on cancer progression.
Main Methods:
- Biochemical assays to detect RKIP-GSK3β binding.
- Western blotting to assess protein levels and phosphorylation states.
- Analysis of signaling pathways including p38 MAPK, Wnt, and epithelial-mesenchymal transition markers.
Main Results:
- RKIP directly binds to GSK3 proteins, maintaining GSK3β protein levels and its active form.
- RKIP depletion leads to oxidative stress-induced p38 MAPK activation, phosphorylating and inactivating GSK3β at T390.
- This inactivation de-represses GSK3β targets, stabilizing cyclin D for cell-cycle progression and increasing β-catenin, SNAIL, and SLUG, promoting epithelial-mesenchymal transition.
- RKIP levels positively correlate with GSK3β expression in human colorectal cancer.
Conclusions:
- The RKIP/GSK3 axis is crucial for maintaining GSK3β activity and suppressing oncogenic signaling.
- Dysregulation of this axis promotes cancer progression, invasion, and metastasis.
- The RKIP/GSK3 axis represents a potential therapeutic target and prognostic biomarker for cancer.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Receptor Tyrosine Kinases
cAMP-dependent Protein Kinase Pathways
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
